PFK-158 was discovered and developed by ACT and was based on the initial drug discovered at the University of Louisville’s James Graham Brown Cancer Center, a part of KentuckyOne Health. The cancer center began recruiting patients for clinical trials in May 2014. Within weeks of opening the first clinical trial site, ACT was able to open the second clinical trial site, Georgetown University Medical Center in Washington, also in May 2014.
“We were pleased to partner with MD Anderson and UT Health Science Center at San Antonio to expand the number of clinical trial sites for PFK-158,” said ACT President and CEO Randall B. Riggs. “PFK-158 is a first-in-man, novel anti-cancer drug that prevents tumor cells from using glucose as a fuel source for tumor survival, growth and metastasis and is currently in a Phase 1 clinical study in the United States.”
In November 2014, PFK-158 was chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch.”
PFK-158 is a small molecule that inactivates a novel cancer metabolism target never before examined in human clinical trials. Last spring, the U.S. Food and Drug Administration (FDA) approved a Phase 1 dose escalation study that is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as prostate, lung, ovarian, melanoma, breast and pancreatic cancer.
PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to undergo clinical trial testing in cancer patients. The target, PFKFB3, is activated by oncogenes and the low oxygen state in cancers, stimulates glucose metabolism and is required for the growth of cancer cells.
PFK-158, which has been licensed by ACT from the James Graham Brown Cancer Center, inhibits the substrate binding domain of PFKFB3 causing a marked reduction in the glucose uptake and growth in multiple preclinical cancer models.
About Advanced Cancer Therapeutics (ACT):
ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. For more information, please visit www.advancedcancertherapeutics.com.
About the James Graham Brown Cancer Center:
The James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center. As part of the region’s leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings. The JGBCC is a part of KentuckyOne Health and is affiliated with the Kentucky Cancer Program. It is the only cancer center in the region to use a unified approach to cancer care, with multidisciplinary teams of physicians working together to guide patients through diagnosis, treatment and recovery. For more information, visit our web site, www.browncancercenter.org.
